

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/173723 A1

(51) International Patent Classification:

A61K 31/704 (2006.01) A61P 35/00 (2006.01)
A61K 38/13 (2006.01) A61P 35/04 (2006.01)
A61K 45/06 (2006.01)

08837 (US). **FOSTER, Robert, T.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(74) Agent: **CHANG, Y., Paul**; Sheppard Mullin Richter & Hampton LLP, 12275 El Camino Real, Suite 100, San Diego, CA 92130 (US).

(21) International Application Number:

PCT/US2021/019480

(22) International Filing Date:

24 February 2021 (24.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/981,383 25 February 2020 (25.02.2020) US

(71) Applicant: **HEPION PHARMACEUTICALS, INC.**
[US/US]; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: USE OF CYCLOSPORINE ANALOGUES FOR TREATING CANCER




FIG. 1A

(57) Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating proliferative diseases such as cancer. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*